Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Borderline ovarian tumors.

J T Chambers1, M J Merino, E I Kohorn

  • 1Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510.

American Journal of Obstetrics and Gynecology
|November 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Results of a fast-track HIV and hepatitis C screening protocol in Barcelona, Spain.

PloS one·2025
Same author

Use of the flavonoid taxifolin for sperm cryopreservation from the threatened Bermeya goat breed.

Theriogenology·2023
Same author

Efficiency of the EmERGE Pathway to provide continuity of care for Spanish people living with medically stable HIV.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2022
Same author

Efficiency of the EmERGE Pathway to provide continuity of care for Spanish people living with medically stable HIV.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2021
Same author

First-in-human phase 0 study of <sup>111</sup>In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Journal of translational science·2019
Same author

Do imaging techniques, grey scale ultrasound, color doppler flow ultrasound and magnetic resonance imaging provide clinically useful information during the therapy of nonmetastatic gestational trophoblastic neoplasia.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2018
Same journal

Association of Surgical Approach with Oncologic Outcomes in Low-Risk Cervical Cancer.

American journal of obstetrics and gynecology·2026
Same journal

Trends in Infertility Treatments by Race, Ethnicity, Socioeconomic Status, and Region in U.S. Birth Certificates from Live Births: 2011-2022.

American journal of obstetrics and gynecology·2026
Same journal

Likelihood ratios enhance clinical interpretation of metagenomic prediction of early-onset neonatal sepsis in preterm premature rupture of membranes (Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Taking risk stratification in preterm premature rupture of membranes to the bedside (Reply to Letter-to-the-Editor).

American journal of obstetrics and gynecology·2026
Same journal

Gestational Age at Full-Term Delivery and Long-Term Offspring Morbidity in Low-Risk Pregnancies: A Population-Based Cohort Study.

American journal of obstetrics and gynecology·2026
Same journal

Trajectories of childbirth-related posttraumatic stress symptoms after a vaginal delivery: a multicenter prospective study.

American journal of obstetrics and gynecology·2026
See all related articles

This retrospective analysis of borderline ovarian tumors found no significant survival benefit from adjuvant therapy. Overall survival was high, suggesting current treatments are effective for these rare gynecologic cancers.

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Clinical Medicine

Background:

  • Borderline ovarian tumors (BOTs) are a distinct group of neoplasms with malignant potential.
  • Understanding their clinical features, treatment patterns, and survival outcomes is crucial for patient management.

Purpose of the Study:

  • To retrospectively analyze clinical features, treatment modalities, and survival characteristics of patients diagnosed with borderline ovarian tumors.
  • To evaluate the efficacy of adjuvant therapies in patients with borderline ovarian tumors.

Main Methods:

  • Retrospective analysis of 94 patients with borderline ovarian tumors.
  • Data collected included FIGO stage, surgical procedures, adjuvant therapies (melphalan, radiation, cisplatin-based chemotherapy), and follow-up duration.

Related Experiment Videos

  • Survival rates and outcomes of second-look surgery were assessed.

    • Main Results:

    • The study included patients across various FIGO stages (IA to IIIC).
    • Common surgical procedures included total abdominal hysterectomy with bilateral salpingo-oophorectomy and conservative surgeries.
    • Overall 5-year survival was 83.0%. Patients receiving adjuvant therapy showed a survival rate of 79.5% compared to 84.6% for those without.
    • Second-look surgery revealed negative results in most cases, regardless of adjuvant treatment, with two positive cases identified.

    Conclusions:

    • This review did not demonstrate a significant benefit of adjuvant therapy for patients with borderline ovarian tumors.
    • High overall survival rates suggest that standard surgical management may be sufficient for many BOT cases.
    • Further prospective studies may be warranted to definitively establish the role of adjuvant treatments in specific subgroups of BOTs.